单中心Afirma与Thyroseq在不确定甲状腺结节中的检测经验
该回顾性研究纳入2014年1月至2020年1月单中心接受Afirma GEC、GSC或Thyroseq v3检测的细胞学不确定甲状腺结节,比较检测性能并与原始验证研究比较。结果显示GSC良性呼叫率78%高于GEC的60%和Thyroseq的66%,GSC特异性73.7%和PPV 61.5%均高于GEC(60.4%、22.2%)和Thyroseq v3(55.2%、18.8%)。
要点
- GSC良性呼叫率78%,高于GEC的60%和Thyroseq的66%。
- GSC特异性73.7%、PPV 61.5%,均高于GEC和Thyroseq v3。
- Thyroseq v3特异性55.2%、PPV 18.8%,与GEC相近但远低于验证研究。
核心结论
- GSC较Afirma GEC将更多细胞学不确定结节归类为良性,且特异性和PPV更高,与验证研究及其他机构经验相似。
- Thyroseq v3在特异性和PPV方面与Afirma GEC相似,但两者均远低于验证研究。
研究设计与样本
- 单中心回顾性研究,纳入2014年1月至2020年1月接受Afirma GEC、GSC或Thyroseq v3分子检测的甲状腺结节。
主要发现
- 良性呼叫率:Afirma GSC组78%,GEC组60%,Thyroseq组66%。
- 手术组织病理学恶性:GEC组31个活检结节中6个,GSC组13个中8个,Thyroseq v3组16个中3个。
- GSC特异性73.7%、PPV 61.5%,高于GEC特异性60.4%、PPV 22.2%及Thyroseq v3特异性55.2%、PPV 18.8%。
临床怎么用
- 在细胞学不确定甲状腺结节中,GSC可提高良性呼叫率并改善特异性与PPV,有助于指导随访或手术决策。
- 本机构Thyroseq v3的实际特异性与PPV低于验证研究,解读结果时需结合本地数据。
局限性
- 为单中心短期经验,样本量有限,各检测组活检结节数较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Thyroid nodules are a very common often incidental finding on physical examination or imaging. Of those who undergo fine needle aspiration, cytology is indeterminate in up to 15%. Molecular testing is increasingly being used to help identify which nodules may be high risk for malignancy and guide management with regard to clinical follow-up or surgical intervention. Recently there has been an increase in publication of independent studies assessing the performance of these molecular tests and comparing "real-world" data with the validation studies. Methods: This retrospective study identified all thyroid nodules at our institution that had Afirma gene expression classifier (GEC), genomic sequencing classifier (GSC), or Thyroseq v3 molecular testing from January 2014 to January 2020 and compared measurements of test performance between them at our institution, and then with the original validation studies and other published institutional data. Results: Overall, the benign call rate was highest in the Afirma GSC group (78%) compared with the GEC group (60%) and Thyroseq group (66%). Surgical histopathology revealed malignancy in 6 of 31of biopsied nodules in the GEC group, 8 of 13 in the GSC group, and 3 of 16 in the Thyroseq v3 group. Based on our data, the GSC specificity (73.7%) and positive predictive value (PPV) (61.5%) were higher than the GEC specificity (60.4%) and PPV (22.2%) as well as Thyroseq v3 specificity (55.2%) and PPV (18.8%). Conclusions: From our short-term institutional experience, we found that the GSC classified more cytologically indeterminate nodules as benign compared with the Afirma GEC, and had improved specificity and PPV, which is similar to the validation study and other institutions' reported experiences. We also found that the Thyroseq v3 was similar to the Afirma GEC in terms of specificity and PPV, both of which are much lower than the validation studies.
引用
- Gortakowski M, Feghali K, Osakwe I, et al. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules. Thyroid. 2021. PMID: 33764195. doi:10.1089/thy.2020.0801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。